Share Name | Share Symbol | Market | Type |
---|---|---|---|
GeneLink Inc (CE) | USOTC:GNLKQ | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 00:00:00 |
UNITED STATE S SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549
FORM 12b-25 NOTIFICATION OF LATE FILING
(Check One) [X] Form 10-K [_] Form 20-F [_] Form 11-K [_] Form 10-Q [_] Form N-SAR
For Period Ended: December 31, 2013 [_] Transition Report on Form 10-K [_] Transition Report on Form 20-F [_] Transition Report on Form 11-K [_] Transition Report on Form 10-Q [_] Transition Report on Form N-SAR For the Transition Period Ended: ________________________
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
GENELINK, INC.
Full Name of Registrant:
Former Name if Applicable 8250 Exchange Dr. Suite 120
Address of Principal Executive Office (Street and Number) Orlando, FL, 32809
City, State, Zip Code
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
X | (a) | The reasons described in reasonable detail in Part III of this form could not be eliminated |
without unreasonable effort or expense; | ||
X | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, |
11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day | ||
following the prescribed due date; or the subject quarterly report of transition report on Form | ||
10-Q, or portion thereof will be filed on or before the fifth calendar day following the | ||
prescribed due date; and | ||
(c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if | |
applicable. |
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR or the transition report or portion thereof could not be filed within the prescribed time period.
The Registrant encountered difficulties in completing the accounting and reporting for certain disclosures and could not complete the report in sufficient time to permit the filing of the 10-K without unreasonable expense and effort.
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
GENELINK, INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: April 1, 2014___________ By: /s/ Michael G. Smith____________ Chief Operating Officer
1 Year GeneLink (CE) Chart |
1 Month GeneLink (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions